A Study to Learn About the Study Medicine Called PF-07799544 in People With Advanced Solid Tumors

Launched by PFIZER · Sep 9, 2022

Keywords

ClinConnect Summary

This clinical trial is studying a new medicine called PF-07799544 to see how safe and effective it is for people with advanced solid tumors, such as melanoma, brain cancer, thyroid cancer, and lung cancer, among others. The trial is looking for participants who have cancer that has not responded well to other treatments. Everyone who joins the study will take PF-07799544 as a daily tablet, and some participants may also receive another medicine to see how they work together. The trial will last for about two years, and participants will be closely monitored by the study team during regular visits.

To be eligible for the trial, participants must have a specific type of advanced cancer that has progressed after previous treatments and have no other effective options available. For certain parts of the study, additional requirements related to specific genetic changes in the tumor may apply. This study is currently recruiting participants of all genders aged 18 and older. If you're considering joining, you'll get to learn more about how the study works, what to expect during treatment, and the support available from the medical team.

Gender

ALL

Eligibility criteria

• Inclusion Criteria:
• • Diagnosis of advanced/metastatic solid tumor including primary brain tumor for monotherapy phase 1a dose escalation
• • Disease progressed during/following last prior treatment and no satisfactory alternative treatment options for monotherapy phase 1a dose escalation
• • For Substudy B, histological or cytological diagnosis of advanced/metastatic melanoma
• • For Substudy C, unresectable or adv/metastatic solid tumor progressed on, or with demonstrated intolerance to SOC, excluding melanoma,
• • For Substudy B and C, measurable disease by RECIST version 1.1
• • For Substudy B, evidence of a BRAF V600 mutation or BRAF Class II/III alteration in tumor tissue and/or blood
• • For Substudy C, evidence of a BRAF founder alteration (non-V600 Class II/III BRAF alteration)
• Exclusion Criteria:
• • Brain metastasis larger than 4 cm
• • History or current evidence of retinal vein occlusion (RVO) or concurrent neuromuscular disorder associated with elevated creatine kinase (CK)